GCT strengthens science development team with top appointment of biotech and medical research veteran M. Karen Newell Rogers
SAN DIEGO, June 2, 2021 /PRNewswire/ — Global Cancer Technology—the cancer research company using invisible dots to solve visible problems in healthcare—today announced the appointment of M. Karen Newell Rogers, Ph.D., as Chief Scientific Consultant and Advisor, a move that will strengthen GCT’s research efforts in glioblastoma, nanoparticle technology, and X-ray activated therapeutic delivery systems.
In this role, Dr. Newell Rogers will coordinate collaborations with Barrow Neurological Institute, and scientists from the University of California San Diego as the team conducts pre-clinical studies towards the commercialization of a new glioblastoma treatment. She is also tasked with managing relationships and research efforts across GCT’s other cancer and technology endeavors, including developing nanoparticle technologies for hospital and surgery center applications, and clinical trials for real-time trackable X-ray-activated therapeutics for glioblastoma and other cancers.
Dr. Newell Rogers brings a wealth of experience in biotechnology and cancer research to her new position at GCT, including her current role as Chief Scientific Officer at BCell Solutions. Previously, Dr. Newell Rogers was the Chief Scientific Officer for Aspire Biotechnology, Inc., and an adjunct professor and Senior Research Professor at the Trauma Health and Hazards Center at the University of Colorado-Colorado Springs. She has actively pursued research in physiology, biotechnology, neurology, biology, surgery, and immunology.
Newell Rogers holds a Ph.D. in Microbiology and Immunology from the University of Colorado and a Bachelor’s degree in Microbiology from the University of Texas at Austin. She completed post-doctoral fellowships at the National Jewish Center for Immunology and Respiratory Medicine, McGill University, the Medical Research Council of Canada, and the Leukemia Society of America.
In addition to her new role at GCT, Dr. Newell Rogers will continue to serve as a Research Professor in the Department of Medical Physiology at Texas A&M Health Sciences Center, the Chief Scientific Officer at BCell Solutions, Inc., and an adjunct faculty member at the Barrow Neurological Institute.
The addition of Newell Rogers to the GCT team comes on the heels of the company’s mini-IPO, which launched earlier this month on Manhattan Street Capital after the SEC previously qualified the company to raise $9 million under a Reg A+ registration. These forward movements represent significant investments by GCT to advance its efforts in the development of novel cancer-delivery technology and innovative new treatments for deadly diseases.
“We are thrilled to welcome Dr. Newell Rogers to the team at Global Cancer Technology. Her wealth of knowledge and experience in biotechnology and medical research is essential in our efforts to complete pre-clinical trials for new treatments for glioblastoma with our partners at UCSD and Barrow Neurological Institute,” said John P. Clark, CEO of GCT. “Karen is joining us at a very exciting time when we are starting to see initial positive outcomes from our pre-clinical trials in the fight against glioblastoma. We are focused on making a difference in medical and cancer research, and Karen’s expertise is going to help us change the future for not only scientists and doctors, but for patients and their families.”
About Global Cancer Technology Global Cancer Technology (GCT) is an emerging biopharmaceutical company that is pre-revenue and financially operates as a medical technology holding company. GCT holds numerous patents and other assets including licenses to commercialize nanoparticle technology for the treatment of COVID-19, cancer and other diseases requiring targeted therapeutic delivery. In collaboration with highly acclaimed academic institutions such as UCSD and Barrow Neurological Institute, along with recognized industry leaders, GCT aims to make novel therapies available to patients as quickly as possible. The company has already raised $1 million in a private placement. The SEC has recently qualified GCT to commence raising $9 Million under a Reg A+ registration.
Media Contact: Amy C. Oliver 801-783-9067 firstname.lastname@example.org
“THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM: https://www.manhattanstreetcapital.com/offering-circular/26358 YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.”
View the original press release here.